Thrivent Financial For Lutherans Eagle Pharmaceuticals, Inc. Transaction History

Thrivent Financial For Lutherans

$52.6 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$25.06 - $34.09 $9,071 - $12,340	-362 Reduced 3.39%	10,319 $293,000
Q4 2022 Feb 08, 2023	SELL	$24.98 - $39.77 $7,618 - $12,129	-305 Reduced 2.78%	10,681 $312,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $184 - $329	7 Added 0.06%	10,986 $290,000
Q2 2022 Aug 16, 2022	BUY	$41.26 - $51.35 $71,297 - $88,732	1,728 Added 18.68%	10,979 $488,000
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $133 - $157	3 Added 0.03%	9,251 $458,000
Q4 2021 Feb 16, 2022	SELL	$45.82 - $56.9 $3,115 - $3,869	-68 Reduced 0.73%	9,248 $471,000
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $9,721 - $12,383	-222 Reduced 2.33%	9,316 $520,000
Q2 2021 Aug 19, 2021	BUY	$36.86 - $44.5 $442 - $534	12 Added 0.13%	9,538 $408,000
Q1 2021 May 17, 2021	SELL	$40.32 - $50.97 $2,943 - $3,720	-73 Reduced 0.76%	9,526 $398,000
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $18,481 - $22,743	-443 Reduced 4.41%	9,599 $447,000
Q3 2020 Nov 10, 2020	BUY	$37.02 - $51.28 $57,862 - $80,150	1,563 Added 18.43%	10,042 $427,000
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $14,572 - $25,469	424 Added 5.26%	8,479 $390,000
Q4 2019 Feb 13, 2020	BUY	$54.32 - $64.31 $1,032 - $1,221	19 Added 0.24%	8,055 $484,000
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $2,556 - $2,879	-48 Reduced 0.59%	8,036 $455,000
Q2 2019 Aug 13, 2019	SELL	$46.61 - $58.45 $14,635 - $18,353	-314 Reduced 3.74%	8,084 $450,000
Q1 2019 May 14, 2019	BUY	$38.66 - $51.82 $26,018 - $34,874	673 Added 8.71%	8,398 $424,000
Q4 2018 Feb 15, 2019	BUY	$36.72 - $67.73 $6,205 - $11,446	169 Added 2.24%	7,725 $311,000
Q3 2018 Nov 15, 2018	BUY	$66.65 - $83.86 $123,102 - $154,889	1,847 Added 32.35%	7,556 $524,000
Q2 2018 Aug 14, 2018	BUY	$51.25 - $76.62 $18,552 - $27,736	362 Added 6.77%	5,709 $432,000
Q1 2018 May 08, 2018	BUY	$52.16 - $66.86 $1,669 - $2,139	32 Added 0.6%	5,347 $282,000
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $5,208 - $6,391	105 Added 2.02%	5,315 $284,000
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $242,890 - $314,475	5,210	5,210 $311,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account